GRA8 DNA vaccine formulations protect against chronic toxoplasmosis

Karakavuk, Muhammet; Can, Hüseyin; Gül, Aytül; Döşkaya, Aysu Değirmenci; Alak, Sedef Erkunt; Ün, Cemal; Gürüz, Adnan Yüksel; Döşkaya, Mert

doi:10.1016/j.micpath.2021.105016

Cited by 8 publications

(9 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Toxoplasmosis is one of the most challenging and opportunistic protozoan disease in public health. The absence of safe and effective vaccine or drugs to eradicate toxoplasmosis remains one of the great global challenges (Karakavuk et al 2021), many medicines becoming resistant and having high toxic side effects. Hence, safe and e cient anti-Toxoplasma drugs is urgent needed.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the effect and mechanism of artemether against Toxoplasma gondii

Duan

Pan

et al. 2023

Preprint

View full text Add to dashboard Cite

This study aimed to investigate compounds that has anti-Toxoplasma gondii with the possible advantage of limiting drug resistance. Artemether has potential anti-T. gondii activity, however the detail information is not clear. To evaluate the Specific effect and potential mechanism, in this study, the cytotoxicity of artemether was Firstly evaluated using MTT assay. Secondly, the anti-T. gondii activities was determined using plaque assay, and then the invasion and intracellular proliferation were evaluated. Finally, the mitochondrial membrane potential and reactive oxygen species (ROS) of T. gondii were detected by the JC-1 probe and automatic microplate reader. The safe concentration of artemether is below 7.042 mM on HFF cells, and artemether exhibited good anti-T. gondii activity with the IC50 = 0.905 mM, it can inhibit T. gondii intracellular proliferation by decreasing T. gondii mitochondrial membrane integrity and increasing ROS production.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of the effect and mechanism of artemether against Toxoplasma gondii

Duan

Pan

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Liposomes, mainly composed of the phospholipid bilayer, have been approved by FDA for drug delivery and other biological fields because of their simple structure, safety, and biodegradability. Liposomal vaccines have been widely studied for cancer, bacteria, virus, parasites’ prevention, and control. − …”

Section: Lipid-based Materialsmentioning

confidence: 99%

Nanotechnology-Based Approaches to Promote Lymph Node Targeted Delivery of Cancer Vaccines

Zang

Zhao

et al. 2022

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Vaccines are a promising immunotherapy that awakens the human immune system to inhibit and eliminate cancer with fewer side effects compared with traditional radiotherapy and chemotherapy. Although cancer vaccines have shown some efficacy, there are still troublesome bottlenecks to expand their benefits in the clinic, including weak immune effects and limited therapeutic outcomes. In the past few years, in addition to neoantigen screening, a main branch of the efforts has been devoted to promoting the lymph nodes (LNs) targeting of cancer vaccines and the cross-presentation of antigens by dendritic cells (DCs), two cardinal stages in effective initiation of the immune response. Especially, nanomaterials have shown hopeful biomedical applications in the improvement of vaccine effectiveness. This Review briefly outlines the possible mechanisms by which nanoparticle properties affect LN targeting and antigen cross-presentation and then gives an overview of state-of-the-art advances in improving these biological outcomes with nanotechnology.

show abstract

“…Proliferation of the lymphocytes was detected using an MTT assay (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) as previously described [22]. Briefly, the lymphocytes in the spleen were isolated using a lymphocyte separation medium kit (Solarbio Life Science).…”

Section: Mtt Assaymentioning

confidence: 99%

Heterologous Prime-Boost Immunization with DNA Vaccine and Modified Recombinant Proteins Enhances Immune Response against Trueperella pyogenes in Mice

et al. 2022

View full text Add to dashboard Cite

Trueperella pyogenes (T. pyogenes) is a crucial opportunistic pathogen normally causing mastitis, abscesses and pneumonia in economically important ruminants. Although only one commercial vaccine of T. pyogenes is currently obtainable, its immunoprotective effect is limited. Pyolysin (PLO) is the most predominant virulence factor highly expressed in T. pyogenes and is an excellent target for the development of novel vaccines against T. pyogenes. In this study, we designed a heterologous prime-boost vaccination scheme combining a DNA vaccine pVAX1-PLO and a subunit vaccine His-PLO to maximize host responses in mice. Humoral and cellular immune responses and protective effects were evaluated in mice to compare the immunogenicity induced by different immunization schemes. Compared to the PBS-control group, in vivo immunization results showed that better immune responses of mice immunized with the pVAX1-PLO plasmids and His-PLO proteins were induced. The residual bacterial burdens from the liver and peritoneal fluid were remarkably decreased in the immunized mice compared with the PBS group. Notably, the heterologous prime-boost vaccination groups significantly enhanced host humoral and cellular immune responses and protected mice from different virulent T. pyogenes strains infection. Conclusively, this study provides a favorable strategy for the further development of next-generation vaccines against T. pyogenes infections.

show abstract

GRA8 DNA vaccine formulations protect against chronic toxoplasmosis

Cited by 8 publications

References 46 publications

Evaluation of the effect and mechanism of artemether against Toxoplasma gondii

Evaluation of the effect and mechanism of artemether against Toxoplasma gondii

Nanotechnology-Based Approaches to Promote Lymph Node Targeted Delivery of Cancer Vaccines

Heterologous Prime-Boost Immunization with DNA Vaccine and Modified Recombinant Proteins Enhances Immune Response against Trueperella pyogenes in Mice

Contact Info

Product

Resources

About